Skip to main content
Top

16-01-2024 | Telemedicine | Original Research: Qualitative Research

Patients’ and Clinicians’ Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study

Authors: Tamar Wyte-Lake, DPT, MPH, Deborah J. Cohen, PhD, Shannon Williams, MSc, David Casey, MSW, LCSW, CADC II, Matt Chan, MD, Brian Frank, MD, Ximena A. Levander, MD, Dan Stein, PA-C, Katie Kirkman White, MSW, LCSW, MAC, Steffani R. Bailey, PhD

Published in: Journal of General Internal Medicine

Login to get access

Abstract

Background

Opioid use disorder (OUD) is a chronic condition that requires regular visits and care continuity. Telehealth implementation has created multiple visit modalities for OUD care. There is limited knowledge of patients’ and clinicians’ perceptions and experiences related to multi-modality care and when different modalities might be best employed.

Objective

To identify patients’ and clinicians’ experiences with multiple visit modalities for OUD treatment in primary care.

Design

Comparative case study, using video- and telephone-based semi-structured interviews.

Participants

Patients being treated for OUD (n = 19) and clinicians who provided OUD care (n = 15) from two primary care clinics within the same healthcare system.

Approach

Using an inductive approach, interviews were analyzed to identify patients’ and clinicians’ experiences with receiving/delivering OUD care via different visit modalities. Clinicians’ and patients’ experiences were compared using a group analytical process.

Key Results

Patients and clinicians valued having multiple modalities available for care, with flexibility identified as a key benefit. Patients highlighted the decreased burden of travel and less social anxiety with telehealth visits. Similarly, clinicians reported that telehealth decreased medical intrusion into the lives of patients stable in recovery. Patients and clinicians saw the value of in-person visits when establishing care and for patients needing additional support. In-person visits allowed the ability to conduct urine drug testing, and to foster relationships and trust building, which were more difficult, but not impossible via a telehealth visit. Patients preferred telephone over video visits, as these were more private and more convenient. Clinicians identified benefits of video, including being able to both hear and see the patient, but often deferred to patient preference.

Conclusions

Considerations for utilization of visit modalities for OUD care were identified based on patients’ needs and preferences, which often changed over the course of treatment. Continued research is needed determine how visit modalities impact patient outcomes.
Appendix
Available only for authorised users
Literature
20.
go back to reference Huskamp HA, Riedel L, Campa I, et al. Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians. J Gen Int Med. 2023:1-8. Huskamp HA, Riedel L, Campa I, et al. Long-Term Prospects for Telemedicine in Opioid Use Disorder (OUD) Treatment: Results from a Longitudinal Survey of OUD Clinicians. J Gen Int Med. 2023:1-8.
22.
go back to reference Duff N, Freiling E, Burstin H, Clark K, Salman A. NAM Action Collaborative on Countering the U.S. Opioid Epidemic Telehealth and Virtual Care Meeting Series: Introduction to Improving Telehealth and Virtual Care for Pain Management and Opioid/Substance Use Disorder. 2022 Duff N, Freiling E, Burstin H, Clark K, Salman A. NAM Action Collaborative on Countering the U.S. Opioid Epidemic Telehealth and Virtual Care Meeting Series: Introduction to Improving Telehealth and Virtual Care for Pain Management and Opioid/Substance Use Disorder. 2022
28.
go back to reference Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Ame J Eval. 2006;27(2):237-246.CrossRef Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Ame J Eval. 2006;27(2):237-246.CrossRef
33.
go back to reference Frost MC, Zhang L, Kim HM, Lin LA. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Network Open. 2022;5(10):e2236298-e2236298.CrossRefPubMedPubMedCentral Frost MC, Zhang L, Kim HM, Lin LA. Use of and retention on video, telephone, and in-person buprenorphine treatment for opioid use disorder during the COVID-19 pandemic. JAMA Network Open. 2022;5(10):e2236298-e2236298.CrossRefPubMedPubMedCentral
35.
go back to reference National Trends in Telehealth Use in 2021:Disparities in Utilization and Audio vs. Video Services.(Research Report No.HP-2022-04) (Office of the Assistant Secretary for Planning and Evaluation, U. S. Department of Health and Human Services) (February 2022). National Trends in Telehealth Use in 2021:Disparities in Utilization and Audio vs. Video Services.(Research Report No.HP-2022-04) (Office of the Assistant Secretary for Planning and Evaluation, U. S. Department of Health and Human Services) (February 2022).
38.
go back to reference Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. Journal of substance abuse treatment. 2021;122:108219.CrossRef Joseph G, Torres-Lockhart K, Stein MR, Mund PA, Nahvi S. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19. Journal of substance abuse treatment. 2021;122:108219.CrossRef
41.
go back to reference Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. In: Drug Enforcement Administration, editor. 88 FR 300372023. 30037-30043. Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. In: Drug Enforcement Administration, editor. 88 FR 300372023. 30037-30043.
42.
go back to reference Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees. JAMA network open. 2023;6(10):e2336914-e2336914.CrossRefPubMedPubMedCentral Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees. JAMA network open. 2023;6(10):e2336914-e2336914.CrossRefPubMedPubMedCentral
43.
go back to reference Pham H, Lin C, Zhu Y, et al. Telemedicine-delivered treatment for substance use disorder: A scoping review. J Telemed Telecare. 2023:1357633X231190945. Pham H, Lin C, Zhu Y, et al. Telemedicine-delivered treatment for substance use disorder: A scoping review. J Telemed Telecare. 2023:1357633X231190945.
Metadata
Title
Patients’ and Clinicians’ Experiences with In-person, Video, and Phone Modalities for Opioid Use Disorder Treatment: A Qualitative Study
Authors
Tamar Wyte-Lake, DPT, MPH
Deborah J. Cohen, PhD
Shannon Williams, MSc
David Casey, MSW, LCSW, CADC II
Matt Chan, MD
Brian Frank, MD
Ximena A. Levander, MD
Dan Stein, PA-C
Katie Kirkman White, MSW, LCSW, MAC
Steffani R. Bailey, PhD
Publication date
16-01-2024
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-023-08586-6
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare